metoclopramide has been researched along with Adenoma, Prolactin-Secreting, Pituitary in 13 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The response profile of total and monomeric prolactin following the administration of metoclopramide was similar in women with monomeric hyperprolactinemia and normoprolactinemia but different in women with macroprolactinemia." | 7.85 | Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia. ( Calaf, J; Espinós, JJ; Gich, I; Urgell, E; Vanrell, C, 2017) |
| "A patient with a rare combination of prolactinoma and aldosterone producing adrenal adenoma (APA) was reported in relation to studies concerning dopaminergic regulation of PRL and aldosterone secretion." | 5.28 | A patient with a prolactinoma associated with an aldosterone producing adrenal adenoma: differences in dopaminergic regulation of PRL and aldosterone secretion. ( Demura, H; Demura, R; Isawa, M; Naruse, K; Naruse, M; Onoda, N; Yamakado, M, 1992) |
| "The patients with microprolactinomas had a low prolactin response (increments less than 300-400%) and delayed TSH response." | 5.28 | [Pharmacodynamic metoclopramide (cerucal) test in differential diagnosis of hypoprolactinemic hypogonadism syndrome in women]. ( Balabolkin, MI; Gerasimov, GA; Liubimov, AV, 1990) |
| "The effect of YRTJ Granule on metoclopramide-induced hyperprolactinemia was tested in rats." | 3.85 | Paeoniflorin and liquiritin, two major constituents in Chinese herbal formulas used to treat hyperprolactinemia-associated disorders, inhibits prolactin secretion in prolactinoma cells by different mechanisms. ( Batey, R; La, L; Li, Y; Wang, C; Wang, L; Wei, Y, 2017) |
| "The response profile of total and monomeric prolactin following the administration of metoclopramide was similar in women with monomeric hyperprolactinemia and normoprolactinemia but different in women with macroprolactinemia." | 3.85 | Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia. ( Calaf, J; Espinós, JJ; Gich, I; Urgell, E; Vanrell, C, 2017) |
| "Differences between micro- and macroprolactinomas, as regards the prolactin secretory pattern in response to pharmacological challenges, have been reported in in vivo and in vitro models, and interpreted as being due to different dopaminergic regulation of prolactin release." | 2.68 | No difference between micro- and macroprolactinomas in the prolactin responsiveness to metoclopramide and dopamine administration. ( Braga, M; Cavagnini, F; Maraschini, C; Moro, M; Toja, P, 1996) |
| "Twelve patients suffering from macroprolactinoma were treated for at least 6 months with daily doses ranging from 50 up to 300 micrograms." | 1.29 | Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study. ( Althoff, P; Jungmann, E; Nickelsen, T; Schumm-Draeger, PM; Usadel, KH, 1993) |
| "Bromocriptine treatment (10 mg daily p." | 1.29 | Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment. ( Andonova, K; Andreeva, M; Kalinov, K; Matrozov, P; Stoeva, I; Zacharieva, S, 1996) |
| "A patient with a rare combination of prolactinoma and aldosterone producing adrenal adenoma (APA) was reported in relation to studies concerning dopaminergic regulation of PRL and aldosterone secretion." | 1.28 | A patient with a prolactinoma associated with an aldosterone producing adrenal adenoma: differences in dopaminergic regulation of PRL and aldosterone secretion. ( Demura, H; Demura, R; Isawa, M; Naruse, K; Naruse, M; Onoda, N; Yamakado, M, 1992) |
| "The patients with microprolactinomas had a low prolactin response (increments less than 300-400%) and delayed TSH response." | 1.28 | [Pharmacodynamic metoclopramide (cerucal) test in differential diagnosis of hypoprolactinemic hypogonadism syndrome in women]. ( Balabolkin, MI; Gerasimov, GA; Liubimov, AV, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 8 (61.54) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Rodier, C | 1 |
| Courbière, B | 1 |
| Fernandes, S | 1 |
| Vermalle, M | 1 |
| Florence, B | 1 |
| Resseguier, N | 1 |
| Brue, T | 1 |
| Cuny, T | 1 |
| Wei, Y | 1 |
| La, L | 1 |
| Wang, L | 1 |
| Batey, R | 1 |
| Wang, C | 1 |
| Li, Y | 1 |
| Espinós, JJ | 1 |
| Vanrell, C | 1 |
| Gich, I | 1 |
| Urgell, E | 1 |
| Calaf, J | 1 |
| Verhelst, J | 1 |
| Beckers, A | 1 |
| Abs, R | 1 |
| Nickelsen, T | 1 |
| Jungmann, E | 1 |
| Althoff, P | 1 |
| Schumm-Draeger, PM | 1 |
| Usadel, KH | 1 |
| Maraschini, C | 1 |
| Moro, M | 1 |
| Toja, P | 1 |
| Braga, M | 1 |
| Cavagnini, F | 1 |
| Zacharieva, S | 1 |
| Stoeva, I | 1 |
| Andreeva, M | 1 |
| Kalinov, K | 1 |
| Matrozov, P | 1 |
| Andonova, K | 1 |
| Azuma, K | 1 |
| Irahara, M | 1 |
| Aono, T | 1 |
| Demura, R | 1 |
| Naruse, M | 1 |
| Isawa, M | 1 |
| Onoda, N | 1 |
| Naruse, K | 1 |
| Yamakado, M | 1 |
| Demura, H | 1 |
| Klockenbusch, W | 1 |
| Distler, W | 1 |
| von Ditfurth, M | 1 |
| Graf, M | 1 |
| Jahn, K | 1 |
| Balabolkin, MI | 1 |
| Gerasimov, GA | 1 |
| Liubimov, AV | 1 |
| Xia, P | 1 |
| Shi, YF | 1 |
| Ohmichi, M | 1 |
| Koike, K | 1 |
| Miyake, A | 1 |
| Tanizawa, O | 1 |
1 review available for metoclopramide and Adenoma, Prolactin-Secreting, Pituitary
| Article | Year |
|---|---|
[Metoclopramide, sulpiride, and chlorpromazine loading test].
Topics: Chlorpromazine; Humans; Hyperprolactinemia; Metoclopramide; Pituitary Function Tests; Pituitary Glan | 1997 |
1 trial available for metoclopramide and Adenoma, Prolactin-Secreting, Pituitary
| Article | Year |
|---|---|
No difference between micro- and macroprolactinomas in the prolactin responsiveness to metoclopramide and dopamine administration.
Topics: Adolescent; Adult; Dopamine; Female; Humans; Kinetics; Male; Metoclopramide; Middle Aged; Pituitary | 1996 |
11 other studies available for metoclopramide and Adenoma, Prolactin-Secreting, Pituitary
| Article | Year |
|---|---|
Metoclopramide Test in Hyperprolactinemic Women With Polycystic Ovarian Syndrome: Old Wine Into New Bottles?
Topics: Female; Humans; Male; Metoclopramide; Pituitary Neoplasms; Polycystic Ovary Syndrome; Prolactinoma; | 2022 |
Paeoniflorin and liquiritin, two major constituents in Chinese herbal formulas used to treat hyperprolactinemia-associated disorders, inhibits prolactin secretion in prolactinoma cells by different mechanisms.
Topics: Animals; Cell Line, Tumor; Drugs, Chinese Herbal; Female; Flavanones; Glucosides; Hyperprolactinemia | 2017 |
Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia.
Topics: Adult; Dopamine D2 Receptor Antagonists; Female; Humans; Hyperprolactinemia; Metoclopramide; Middle | 2017 |
The effect of naloxone and metoclopramide on the secretion of luteinizing hormone in a hyperprolactinemic hypogonadotropic postmenopausal woman.
Topics: Aged; Bromocriptine; Dopamine Agonists; Dopamine Antagonists; Female; Follicle Stimulating Hormone; | 1995 |
Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
Topics: Adult; Aged; Aminoquinolines; Blood Pressure; Dopamine Agents; Female; Gonadal Steroid Hormones; Gon | 1993 |
Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment.
Topics: Adult; Aldosterone; Bromocriptine; Case-Control Studies; Dopamine Agonists; Dopamine Antagonists; Dr | 1996 |
A patient with a prolactinoma associated with an aldosterone producing adrenal adenoma: differences in dopaminergic regulation of PRL and aldosterone secretion.
Topics: Adenoma; Adrenal Gland Neoplasms; Adult; Aldosterone; Bromocriptine; Dopamine; Female; Humans; Metoc | 1992 |
[The value of functional tests in diagnosis of prolactinoma].
Topics: Circadian Rhythm; Female; Humans; Hyperprolactinemia; Metoclopramide; Pituitary Neoplasms; Prolactin | 1990 |
[Pharmacodynamic metoclopramide (cerucal) test in differential diagnosis of hypoprolactinemic hypogonadism syndrome in women].
Topics: Adult; Diagnosis, Differential; Female; Humans; Hyperprolactinemia; Hypogonadism; Metoclopramide; Pi | 1990 |
Evaluation of hypothalamic dopaminergic function in patients with pituitary prolactinoma.
Topics: Adult; Carbidopa; Female; Humans; Levodopa; Luteinizing Hormone; Metoclopramide; Pituitary Neoplasms | 1989 |
A simple rapid method for prolactin assay by reversed passive hemagglutination: evaluation of its clinical application.
Topics: Amenorrhea; Antibodies, Monoclonal; Bromocriptine; Female; Hemagglutination Tests; Humans; Metoclopr | 1989 |